The CF data definitely looked very interesting but my guess is the FDA might want more for a BT designation. The numbers were not large and the absence of an effect in patients with mild cognitive impairment, which you might expect to be more amenable to reversal than severe dysfunction, might trouble the FDA. Because of that, I think the data RVX is collecting on markers in blood samples will be important. If they are positive then I agree BTD for CF could be on the cards. I think a lot depends on those results.